Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (2553)	6/9/1998 3:39:00 PM
From: Ron Harvey	Read Replies (1) \| Respond to of 5736

<<Officials at Chromatics Color Sciences weren't immediately available for comment.>> There! Isn't that encouraging? And, so there's no doubt, I'm convinced that CCSI's medical device is the real goods and has a large market potential. Too bad they've been postponing PR for the ever-around-the-corner deal announcement.

To: JanyBlueEyes who wrote (2553)	6/9/1998 3:43:00 PM
From: Spunky Beaver	Read Replies (2) \| Respond to of 5736

For what it's worth: The only thing that will turn this stock around now that Asensio has found it is REVENUES. Until that happens, it will continue to fluctuate wildly as it slowly trends down. That' all there is to it. Deal with it whatever way you have too and don't let it ruin your life.

To: JanyBlueEyes who wrote (2553)	6/9/1998 5:54:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 5736

DREYFUS CALLS SHORT SELLER'S ALLEGATIONS "TOTALLY BASELESS" New York, June 9 (Bloomberg)--Dreyfus Corp. denied allegations one of its mutual fund managers may have manipulated the stock of Chromatics Color Sciences International Inc., calling the claim "totally baseless". Manuel Asensio, the president of Asensio & Co., a New YorK-based investment bank that's bet against Chromatics by "short-selling" the company's stock, claims Dreyfus fund manager Michael Shonberg used cash from the fund he manages to keep Chromatics at an "artificially" high price. "Based on our knowledge to date, we believe these allegations are totally baseless," said Patrice Kozlowski, Dreyfus' spokeswoman. Schonberg, co-manager of the $60 million Dreyfus Aggressive Growth Fund, has complied with the company's personal securities trading policies, Kozlowski said. Schonberg wasn't available for comment. Dreyfus, a unit of Mellon Bank Corp., oversees more than $100 billion of mutual fund assets. The Dreyfus Aggressive Growth Fund held about 495,000 shares of Chromatics at the end of February, according to the fund's semiannual report. "What we know to be true is that Schonberg was hired by Dreyfus in August 1995 and proceeded to buy about 1.8 million shares of a company that's had significant losses and no material sales since 1989." Asensio said. "Schonberg is too smart and too experienced to have made this investment unwittingly." Asensio said he's short-selling more than 300,000 shares of Chromatics, which is developing a medical device that helps test infants for jaundice. Short-sellers are speculators who sell borrowed shares in the hope of replacing them at a lower price and hence profiting from a stock's decline. Chromatics shares are down 64 percent since hitting a high on 18 on April 28. The stock fell 2 5/16 today to 6 1/2.